Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 6:50 PM
Ignite Modification Date: 2025-12-25 @ 4:22 PM
NCT ID: NCT03322657
Description: None
Frequency Threshold: 5
Time Frame: Until hospital discharge or 30 days after surgery, which came first
Study: NCT03322657
Study Brief: Sugammadex Versus Neostigmine for Reversal of Rocuronium Neuromuscular
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Sugammadex Sugammadex 4 mg/kg at the end surgery Sugammadex: Sugammadex injection 0 None 0 35 0 35 View
Neostigmine With Glycopyrrolate Neostigmine 0. 07 mg/kg with glycopyrrolate 0.01 mg/kg with ceiling dose of 5 mg neostigmine with 1 mg of glycopyrrolate at the end surgery Neostigmine: Neostigmine injection Glycopyrrolate: Glycopyrrolate injection 0 None 0 33 0 33 View
Serious Events(If Any):
Other Events(If Any):